TAAT Provides Update on Status of Management Cease Trade Order

(TheNewswire)

LAS VEGAS and VANCOUVER – TheNewswire - APRIL 28, 2025 – TAAT®GLOBAL ALTERNATIVES INC. (CSE:TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the“Company” or “TAAT®”) is providing thisupdate on the status of a management cease trade order granted onMarch 3, 2025 (the "MCTO") by the British ColumbiaSecurities Commission under National Policy 12-203 – ManagementCease Trade Order ("NP 12-203"). On March 3, 2025, theCompany announced that, for reasons disclosed in the news release,there would be a delay in the filing of its financial statements andaccompanying management’s discussion and analysis for the fiscalyear ended October 31, 2024 (the "Annual Filings") beyondthe period prescribed under applicable Canadian securities laws (the"Default Announcement").

Due to the additional procedures and added complexitiesof auditing certain transactions during the financial year, and atemporary suspension of the audit process caused by the Company’sfinancial constraints which have since been resolved. The auditprocess has now resumed. The Company applied for, and received anextension of its MCTO by the British Columbia Securities Commission.The Company is now required to complete its Annual Filings by May 14,2025, with the Interim Filings being due for filing within 5 businessdays after the Annual Filings have been filed.

The Company reports that the audit is progressing andwill provide a further update on the timing of its Annual Filings onor about May 12, 2025. The Company is also progressing on completionof its interim financial statements and accompanying management’sdiscussion and analysis for the first quarter ended January 31, 2025,and will provide a further update on or about May 12, 2025. Furtherupdates on timing will be provided by the Company as necessary.

During the MCTO, the general investing public willcontinue to be able to trade in the Company's listed common shares.However, the Company's Chief Executive Office and Chief FinancialOfficer will not be able to trade in the Company's commonshares.

Other than as disclosed in this news release, there areno material changes to the information contained in the DefaultAnnouncement. The Company confirms that it intends to satisfy theprovisions of NP 12-203 and will continue to issue bi-weekly defaultstatus reports for so long as it remains in default of the AnnualFilings requirement.

On behalf of the Board of Directors of theCompany,

TAAT® GLOBAL ALTERNATIVES INC.

“Michael Saxon”

Michael Saxon, CEO and Director

For further information, please contact:

TAAT® Investor Relations

1-833-TAAT-USA (1-833-822-8872)

investor@taatglobal.com

THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOTREVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY ORADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATIONSERVICES PROVIDER.

About TAAT® Global Alternatives Inc.

TAAT® is a vertically integrated consumer product anddistribution company, generating more than CAD $90 million in overallgross revenue annually. TAAT® is strategically expanding its productcategories including tobacco and reduced-risk alternatives, hemp,kratom, and other emerging CPG segments. TAAT® has facilities toinclude a processing plant in Nevada as well as a distribution centrein Canton, Ohio, leveraging existing retail shelf space and pipelinesinto national wholesale channels.

For more information, please visit http://taatglobal.com .

Forward-Looking Statements

Certain information contained herein may constitute"forward-looking information" or "forward-lookingstatements" under Canadian securities legislation. Generally,forward-looking information can be identified by words such as"pro forma", "plans", "expects","may", "should", "could","will", "budget", "scheduled","estimates", "forecasts", "intends","anticipates", "believes", or variations includingnegative variations thereof of such words and phrases that refer tocertain actions, events or results that may, occur or be taken orachieved. Such forward-looking statements, including but not limitedto statements relating to the expected development and operations ofthe Company, statements concerning the timing, review, completion andfiling of the Annual Filings as well as the duration of the MCTO,involve risks, uncertainties and other factors which may cause theactual results to be materially different from those expressed orimplied by such forward-looking statements or forward-lookinginformation. There can be no assurance that such statements will proveto be accurate, as actual results and future events could differmaterially from those anticipated in such statements. Accordingly,readers should not place undue reliance on forward-looking statementsand forward-looking information. The Corporation will not update anyforward-looking statements or forward-looking information includedherein, except as required by applicable securities laws.

The statements in this news release have not beenevaluated by Health Canada or the U.S. Food and Drug Administration.As each individual is different, the benefits, if any, of taking theCompany’s products will vary from person to person. No claims orguarantees can be made as to the effects of the Company’s productson an individual’s health and well-being. The Company’s productsare not intended to diagnose, treat, cure, or prevent anydisease.

This news release may contain trademarked names ofthird-party entities (or their respective offerings with trademarkednames) typically in reference to (i) relationships had by the Companywith such third-party entities as referred to in this release and/or(ii) client/vendor/service provider parties whose relationship withthe Company is/are referred to in this release. All rights to suchtrademarks are reserved by their respective owners orlicensees.

Statement Regarding Third-PartyInvestor Relations Firms

Disclosures relating to investor relations firmsretained by TAAT® Global Alternatives Inc. can be found under theCompany's profile on http://sedarplus.ca .

Copyright (c) 2025 TheNewswire - All rights reserved.